Price T Rowe Associates Inc Adagio Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 25,760 shares of ADGI stock, worth $85,265. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,760Holding current value
$85,265% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding ADGI
# of Institutions
84Shares Held
67.2MCall Options Held
700KPut Options Held
600-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.77% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.19% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million35.29% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.3MShares$14.2 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...